8-K: Artelo Biosciences Faces Nasdaq Delisting Threat

Artelo Biosciences received a delist determination from Nasdaq due to non-compliance with minimum stockholders' equity, but plans to appeal.

Summary

• Artelo Biosciences, Inc. (ARTL) received a delist determination letter from the Nasdaq Stock Market on November 19, 2025.
• The delist determination is a result of the company's non-compliance with Nasdaq Listing Rule 5550(b)(1), which mandates maintaining stockholders' equity of at least $2,500,000.
• The company had previously submitted plans on July 7, 2025, and August 29, 2025, outlining a strategy to regain compliance, which included raising additional capital.
• Nasdaq determined that the anticipated capital raising, crucial for demonstrating compliance, was not completed.
• Artelo Biosciences has until November 26, 2025, to request a hearing panel appeal; otherwise, its securities are scheduled for delisting on December 1, 2025.
• The company intends to appeal Nasdaq's determination, which will allow its common stock to continue trading on Nasdaq under the symbol ARTL during the appeal process.

Sentiment

Score: 3

Explanation: The filing indicates a significant negative event (delisting notice) due to failure to meet financial requirements and complete a planned capital raise. While the company plans to appeal, the underlying financial weakness is a major concern, leading to a low sentiment score.

Positives

• The company intends to appeal Nasdaq's delisting determination, which will allow its common stock to continue trading on Nasdaq under the symbol ARTL during the appeal process, providing temporary liquidity.

Negatives

• Received a delist determination letter from Nasdaq due to non-compliance with the minimum stockholders' equity requirement of $2,500,000.
• Failed to complete the capital raising discussed in previous plans submitted to Nasdaq, which was intended to demonstrate compliance.
• Faces potential delisting from Nasdaq if the appeal is unsuccessful or not filed by the deadline of November 26, 2025.

Risks

• Risk of delisting from The Nasdaq Stock Market if the appeal to the hearing panel is unsuccessful or not pursued by the deadline.
• Failure to meet Nasdaq's continued listing requirements, specifically the $2,500,000 stockholders' equity rule, indicates underlying financial weakness.
• Inability to complete planned capital raising activities, which were crucial for regaining compliance, suggests ongoing funding challenges.

Future Outlook

The company intends to appeal Nasdaq's delist determination to a hearing panel, which, if granted, would stay any further delisting actions through the hearing or any extension provided by the panel. This action aims to maintain the company's listing on Nasdaq, but the underlying financial compliance issue remains to be resolved.

Management Comments

• The Company intends to appeal Nasdaq's determination to a hearing panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series to stay any further delisting actions through the hearing or any extension the hearings panel provides.

Industry Context

This event highlights the ongoing challenges faced by smaller biotechnology companies, particularly those in development stages, in maintaining sufficient capital and meeting stringent exchange listing requirements. The ability to secure funding and maintain a strong balance sheet is critical for these companies to continue operations and advance their pipelines, especially in a competitive and capital-intensive industry.

Stakeholder Impact

• Shareholders: Potential for significant share price volatility and loss of liquidity if delisted from Nasdaq. Uncertainty regarding the company's future listing status and ability to raise capital.
• Creditors: Increased risk perception due to financial non-compliance and potential delisting, which could impact future financing terms and cost of capital.
• Employees: Potential impact on morale and future stability due to the company's financial challenges and listing uncertainty, which could affect talent retention.

Next Steps

• Request a hearing panel appeal of Nasdaq's delist determination by November 26, 2025.
• Present its case to the Nasdaq hearing panel to stay delisting actions and demonstrate a path to compliance with listing rules.

Key Dates

Recommendation

The delist determination from Nasdaq due to failure to meet minimum stockholders' equity and the inability to complete a planned capital raise signals severe financial distress and operational challenges. While an appeal is planned, the fundamental issue of insufficient capital remains. This situation presents significant downside risk, including potential loss of liquidity and further share price depreciation, making a 'sell' recommendation prudent for investors seeking to mitigate exposure to a financially unstable entity.

Keywords

Artelo Biosciences, ARTL, Nasdaq, Delisting, Stockholders' Equity, Listing Rule 5550(b)(1), Capital Raise, SEC Filing, 8-K, Biotechnology, Compliance